ProQR Therapeutics BV (PRQR) - Total Liabilities
Based on the latest financial reports, ProQR Therapeutics BV (PRQR) has total liabilities worth $67.28 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
ProQR Therapeutics BV - Total Liabilities Trend (2012–2024)
This chart illustrates how ProQR Therapeutics BV's total liabilities have evolved over time, based on quarterly financial data. See ProQR Therapeutics BV current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
ProQR Therapeutics BV Competitors by Total Liabilities
The table below lists competitors of ProQR Therapeutics BV ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Cristales
SN:CRISTALES
|
Chile | CL$356.92 Billion |
|
Goodbaby International Holdings Limited
F:GBH
|
Germany | €4.34 Billion |
|
Precision Camshafts Limited
NSE:PRECAM
|
India | Rs2.24 Billion |
|
Thryv Holdings Inc
NASDAQ:THRY
|
USA | $480.72 Million |
|
Kao Fong Machinery Co Ltd
TWO:4510
|
Taiwan | NT$4.11 Billion |
|
Portman Ridge Finance Corp
NASDAQ:PTMN
|
USA | $336.54 Million |
|
Ecomate Holdings Bhd
KLSE:0239
|
Malaysia | RM65.68 Million |
|
Auna S.A.
NYSE:AUNA
|
USA | $5.53 Billion |
Liability Composition Analysis (2012–2024)
This chart breaks down ProQR Therapeutics BV's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see PRQR market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.36 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.18 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.54 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ProQR Therapeutics BV's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ProQR Therapeutics BV (2012–2024)
The table below shows the annual total liabilities of ProQR Therapeutics BV from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $79.40 Million | -25.51% |
| 2023-12-31 | $106.59 Million | +1.86% |
| 2022-12-31 | $104.64 Million | +8.60% |
| 2021-12-31 | $96.35 Million | +86.68% |
| 2020-12-31 | $51.61 Million | +93.99% |
| 2019-12-31 | $26.61 Million | +51.63% |
| 2018-12-31 | $17.55 Million | +27.35% |
| 2017-12-31 | $13.78 Million | +11.05% |
| 2016-12-31 | $12.41 Million | +20.34% |
| 2015-12-31 | $10.31 Million | +76.45% |
| 2014-12-31 | $5.84 Million | +27.22% |
| 2013-12-31 | $4.59 Million | +1821.76% |
| 2012-12-31 | $239.00K | -- |
About ProQR Therapeutics BV
ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-sta… Read more